Allelic analysis of serous ovarian carcinoma reveals two putative tumor suppressor loci at 18q22-q23 distal to SMAD4, SMAD2, and DCC

被引:36
作者
Lassus, H
Salovaara, R
Aaltonen, LA
Butzow, R
机构
[1] Univ Helsinki, Dept Pathol, FIN-00014 Helsinki, Finland
[2] Univ Helsinki, Dept Med Genet, FIN-00014 Helsinki, Finland
[3] Univ Helsinki, Cent Hosp, Dept Obstet & Gynecol, FIN-00014 Helsinki, Finland
关键词
D O I
10.1016/S0002-9440(10)61670-7
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The distal half of chromosome arm 18q is frequently lost in ovarian carcinoma. To define the putative tumor suppressor locus/loci more precisely we performed allelic analysis with 27 polymorphic microsatellite markers located at 18q12.3-q23 in 64 serous and 9 mucinous ovarian carcinomas. Fifty-nine per cent of the serous carcinomas, but only one (11%) of mucinous carcinomas, showed allelic loss at one or more loci (P = 0.018). In serous carcinomas, deletions were found to be associated with tumor grade and poor survival. The highest frequency of losses was detected at the distal part, 18q22-q23. Two minimal common regions of loss (MCRL) were identified at this region: MCRL1 between D18S465 and D18S61 at 18q22 (3.9 cM) and MCRL2 between D18S462 and D18S70 at 18q23 (5.8 cM). At 18q21.1, proximal to the MCRLs, there are three candidate tumor suppressor genes: SMAD4 (DPC4), SMAD2, and DCC. Their protein expression was studied by immunohistochemistry hn normal ovarian tissue and serous carcinomas. Lost or very weak expression of SMAD4, SMAD2 and DCC was found in 28, 28, and 30% of serous carcinomas, respectively. Comparison of allelic loss and protein expression status indicated that none of these genes alone could be the target for the frequent allelic loss at 18q21.1. Together, these genes may account for a substantial proportion of the events, but not all of them. Thus, we propose that the frequent allelic loss at 18q is because of the effect of multiple genes, and there is at least one as yet unidentified tumor suppressor gene at 18q residing distal to SMAD4, SMAD2, and DCC involved in serous ovarian carcinoma.
引用
收藏
页码:35 / 42
页数:8
相关论文
共 38 条
[21]   Genetic alterations distinguish different types of ovarian tumors [J].
Pieretti, M ;
Cavalieri, C ;
Conway, PS ;
Gallion, HH ;
Powell, DE ;
Turker, MS .
INTERNATIONAL JOURNAL OF CANCER, 1995, 64 (06) :434-440
[22]   MUTATIONS OF THE E-CADHERIN GENE IN HUMAN GYNECOLOGIC CANCERS [J].
RISINGER, JI ;
BERCHUCK, A ;
KOHLER, MF ;
BOYD, J .
NATURE GENETICS, 1994, 7 (01) :98-102
[23]   Loss of DCC gene expression during ovarian tumorigenesis: relation to tumour differentiation and progression [J].
Saegusa, M ;
Machida, D ;
Okayasu, I .
BRITISH JOURNAL OF CANCER, 2000, 82 (03) :571-578
[24]  
SATO T, 1991, CANCER RES, V51, P5118
[25]  
Schutte M, 1996, CANCER RES, V56, P2527
[26]   Identification of expressed genes by laser-mediated manipulation of single cells [J].
Schütze, K ;
Lahr, G .
NATURE BIOTECHNOLOGY, 1998, 16 (08) :737-742
[27]   The DCC protein and prognosis in colorectal cancer [J].
Shibata, D ;
Reale, MA ;
Lavin, P ;
Silverman, M ;
Fearon, ER ;
Steele, G ;
Jessup, JM ;
Loda, M ;
Summerhayes, IC .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (23) :1727-1732
[28]  
Suzuki S, 2000, CANCER RES, V60, P5382
[29]  
Takakura S, 1999, GENE CHROMOSOME CANC, V24, P264, DOI 10.1002/(SICI)1098-2264(199903)24:3<264::AID-GCC12>3.0.CO
[30]  
2-Y